# Cardinal Health Inc: Form 10-Q for the period ended Mar 31, 2024

- Company: [Cardinal Health Inc](/companies/cah.md) (CIK 721371)
- Form: 10-Q
- Filed: 2024-05-02
- Accepted by EDGAR: May 2, 2024, 08:47 ET
- Period: 2024-03-31
- Accession: 0000721371-24-000038
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/721371/000072137124000038/cah-20240331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/721371/000072137124000038/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2024-01-01 to 2024-03-31 | $54.91bn | us-gaap:Revenues |
| Revenue | 9 months, 2023-07-01 to 2024-03-31 | $167.12bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2024-01-01 to 2024-03-31 | $52.96bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2023-07-01 to 2024-03-31 | $161.56bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2024-01-01 to 2024-03-31 | $1.95bn | us-gaap:GrossProfit |
| Gross profit | 9 months, 2023-07-01 to 2024-03-31 | $5.56bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2024-01-01 to 2024-03-31 | $1.28bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2023-07-01 to 2024-03-31 | $3.76bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2024-01-01 to 2024-03-31 | $367.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2023-07-01 to 2024-03-31 | $835.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2024-01-01 to 2024-03-31 | $33.0m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2023-07-01 to 2024-03-31 | $55.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2024-01-01 to 2024-03-31 | $82.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2023-07-01 to 2024-03-31 | $186.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-01-01 to 2024-03-31 | $258.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2023-07-01 to 2024-03-31 | $616.0m | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months, 2024-01-01 to 2024-03-31 | 245,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2023-07-01 to 2024-03-31 | 247,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2023-07-01 to 2024-03-31 | $1.69bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2023-07-01 to 2024-03-31 | $318.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2023-07-01 to 2024-03-31 | $377.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months, 2023-07-01 to 2024-03-31 | $750.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2024-03-31 | $3.72bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-03-31 | $35.73bn | us-gaap:AssetsCurrent |
| Total assets | at 2024-03-31 | $45.88bn | us-gaap:Assets |
| Current liabilities | at 2024-03-31 | $36.31bn | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2024-03-31 | −$3.27bn | us-gaap:StockholdersEquity |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/721371/000072137124000038/cah-20240331.htm

Filed May 2, 2024.
Source: SEC EDGAR, the filing index for accession 0000721371-24-000038. Last ingested by Listed: Nov 5, 2026, 12:30 ET. No prices; not investment advice.
